SLCO1B1
ENSG00000134538
Target class
Transporter
Chromosome
12
- Chemical probe available
- No
- Target name
- SLCO1B1
- Gene name
- Solute carrier organic anion transporter family member 1B1
- Gene symbol
- SLCO1B1
- Previous gene symbols
- SLC21A6
- Protein name
- Solute carrier organic anion transporter family member 1B1 (SLCO1B1) (Liver-specific organic anion transporter 1) (LST-1) (OATP-C) (Organic anion transporter SLC21A6) (Sodium-independent organic anion-transporting polypeptide 2) (OATP-2) (Solute carrier family 21 member 6)
- OATP-C
- LST-1
- OATP1B1
- Gene biotype
- Protein coding
- Gene family
- Solute carrier organic anion transporter family
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 1
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 56.74
- Tissue specificity (Gini)
- 0.981
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:10599
- Protein interaction confidence
- 0.815714
- Protein interaction partners
- 35
- R-HSA-159418
- R-HSA-189483
- R-HSA-5619110
- R-HSA-879518
- R-HSA-9754706
- End position
- 21241074
- Start position
- 21131120
- Chromosome
- 12
- Strand
- Forward
- Basolateral cell membrane
- Multi-pass membrane protein . Basal cell membrane
- Multi-pass membrane protein . Note=Detected in basolateral membranes of hepatocytes (PubMed:12196548). Localized to the basal membrane of Sertoli cells (PubMed:35307651). .
- Plasma membrane
- PubMed 12196548
- PubMed 35307651
- Tissue specificity (tau)
- 0.999877
- Expression inequality (Gini)
- 0.981008
Expression in transcripts per million
- Liver
- 56.74
- Testis
- 0.21
- Nerve - Tibial
- 0.06
- Cervix - Endocervix
- 0.04
- Minor Salivary Gland
- 0.03
Expression in transcripts per million
- Liver56.74
- Testis0.21
- Nerve - Tibial0.06
- Cervix - Endocervix0.04
- Minor Salivary Gland0.03
- Brain - Spinal cord (cervical c-1)0.02
- Pituitary0.01
- Vagina0
- Uterus0
- Esophagus - Muscularis0
- Brain - Cerebellar Hemisphere0
- Brain - Caudate (basal ganglia)0
- Bladder0
- Adipose - Subcutaneous0
- Artery - Coronary0
- Stomach0
- Brain - Putamen (basal ganglia)0
- Skin - Not Sun Exposed (Suprapubic)0
- Kidney - Medulla0
- Brain - Frontal Cortex (BA9)0
- Thyroid0
- Colon - Sigmoid0
- Cervix - Ectocervix0
- Breast - Mammary Tissue0
- Brain - Cerebellum0
And 29 more, listed on the interactive page.
- GO:0006805
- GO:0015721
- GO:0042167
- GO:0043252
- GO:0055085
- GO:0005886
- GO:0009925
- GO:0016020
- GO:0016323
- GO:0005515
- GO:0015125
- GO:0015132
- GO:0015291
- GO:0015349
- GO:0022857
regulation of transcription factor activity
- cell-based: LTEA_HepaRG_SLCO1B1is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.
- cell-based: LTEA_HepaRG_SLCO1B1is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.
Biological samples
- HepaRG, cell line
Evidence source
Related records
Trials (1,606)
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients
- 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
- 3D Printing for Nodule Localization
- 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
- A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
- A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers
- A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)
- A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
- A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING)
- A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
Drugs (8)
- Cyclosporine
- Estrone sulfuric acid
- Gemfibrozil
- Glycyrrhizin
- Indocyanine green
- Pravastatin
- Rifampin
- Rifamycin